Accent Group Limited (ASX:AX1)

CTI BioPharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 29, 2024	Jun 30, 2024	Jul 2, 2023	Jun 26, 2022	Jun 27, 2021	Jun 28, 2020
Revenue	1,488	1,454	1,421	1,130	992.75	829.81
Revenue Growth (YoY)	5.94%	2.37%	25.75%	13.80%	19.64%	4.21%
Cost of Revenue	657.2	634.75	624.42	504.99	425.08	356.42
Gross Profit	830.96	819.6	796.27	624.81	567.68	473.39
Selling, General & Admin	462.15	451.9	435.16	361.24	312.72	237.78
Other Operating Expenses	74.27	74.01	66.98	56.45	46.14	40.36
Operating Expenses	698.13	695.07	661.57	561.23	473.89	383.72
Operating Income	132.82	124.53	134.71	63.58	93.78	89.67
Interest Expense	-29.24	-27.84	-20.61	-16.47	-14.9	-15.7
Interest & Investment Income	1.79	1.86	1.43	0.79	1	1.25
EBT Excluding Unusual Items	105.37	98.55	115.53	47.89	79.88	75.23
Asset Writedown	-14.13	-14.13	-	-7.75	-2.08	-2.76
Other Unusual Items	-	-	4.08	6.45	33.2	7.63
Pretax Income	91.24	84.42	119.62	46.59	111	80.09
Income Tax Expense	26.76	24.89	30.96	15.13	34.08	24.58
Earnings From Continuing Operations	64.48	59.53	88.65	31.46	76.92	55.52
Net Income	64.48	59.53	88.65	31.46	76.92	55.52
Net Income to Common	64.48	59.53	88.65	31.46	76.92	55.52
Net Income Growth	-11.14%	-32.85%	181.76%	-59.10%	38.56%	3.06%
Shares Outstanding (Basic)	564	561	549	542	541	540
Shares Outstanding (Diluted)	565	564	568	563	563	561
Shares Change (YoY)	-0.94%	-0.62%	0.82%	-0.03%	0.39%	-0.65%
EPS (Basic)	0.11	0.11	0.16	0.06	0.14	0.10
EPS (Diluted)	0.11	0.11	0.16	0.06	0.14	0.10
EPS Growth	-10.28%	-32.46%	179.43%	-59.08%	37.98%	3.77%
Free Cash Flow	200.44	221.21	230.37	101.54	133.17	159.46
Free Cash Flow Per Share	0.35	0.39	0.41	0.18	0.24	0.28
Dividend Per Share	0.100	0.130	0.175	0.065	0.113	0.092
Dividend Growth	-28.57%	-25.71%	169.23%	-42.22%	21.62%	12.12%
Gross Margin	55.84%	56.35%	56.05%	55.30%	57.18%	57.05%
Operating Margin	8.92%	8.56%	9.48%	5.63%	9.45%	10.81%
Profit Margin	4.33%	4.09%	6.24%	2.79%	7.75%	6.69%
Free Cash Flow Margin	13.47%	15.21%	16.21%	8.99%	13.41%	19.22%
EBITDA	173.43	172.58	181.7	104.49	127.67	119.14
EBITDA Margin	11.65%	11.87%	12.79%	9.25%	12.86%	14.36%
D&A For EBITDA	40.61	48.05	46.99	40.92	33.89	29.47
EBIT	132.82	124.53	134.71	63.58	93.78	89.67
EBIT Margin	8.92%	8.56%	9.48%	5.63%	9.45%	10.81%
Effective Tax Rate	29.33%	29.48%	25.89%	32.47%	30.70%	30.68%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.